Mei‐Hwei Chang, B. Fischler, B. Blauvelt, M. Ciocca, A. Dhawan, U. Ekong, Y. Ni, G. Porta, A. Sibal, Daniele Dagostino, S. Wirth, Neelam Morhan, K. Schwarz
{"title":"Survey of Impediments to Prevention of Mother-to-Infant Transmission of Hepatitis B Virus by International Societies.","authors":"Mei‐Hwei Chang, B. Fischler, B. Blauvelt, M. Ciocca, A. Dhawan, U. Ekong, Y. Ni, G. Porta, A. Sibal, Daniele Dagostino, S. Wirth, Neelam Morhan, K. Schwarz","doi":"10.1097/MPG.0000000000002483","DOIUrl":null,"url":null,"abstract":"Mother-to-infant transmission (MIT) is the leading cause of hepatitis B virus (HBV) infections globally. The aim of this international study was to assess the impediments to prevention of (MIT) of HBV.\n\n\nMETHODS\nA cross-sectional survey was developed by the Federation of the International Societies for Pediatric Gastroenterology, Hepatology and Nutrition. (FISPGHAN) The survey was sent to HBV experts of the five member societies of FISPGHAN, and 63/91 countries/regions responded. Main outcome measures include percentage of countries having vaccine programs, timing of the first dose of HBV vaccine, availability of HBV vaccine for out-born neonates, payment of HBV vaccine and HBIG, screening HBV markers during pregnancy, and antivirals to highly infectious pregnant mothers.\n\n\nRESULTS\nAmong the participating countries/regions, 11% did not implement infant HBV immunization programs. The first dose of vaccine was given >24 hours in 36% of the total countries and 100% of African countries. The recommended birth dose was unavailable for out-born neonates in 45% of the total countries, including 92% of African and 50% of Latin American countries/regions. During pregnancy, 44% countries do not screen maternal viral markers, and 46% do not provide third trimester antiviral therapy for highly viremic pregnant mothers.\n\n\nCONCLUSIONS\nOur study demonstrated multiple obstacles to achieving the goal of preventing MIT of HBV. Comprehensive public health programs to enhance vaccine coverage rate, supply HBV vaccine for out-born neonates, screening maternal HBV markers, treating highly viremic pregnant mothers are proposed to overcome these obstacles and achieve the goal of preventing MIT of HBV.","PeriodicalId":16725,"journal":{"name":"Journal of Pediatric Gastroenterology & Nutrition","volume":"88 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Gastroenterology & Nutrition","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/MPG.0000000000002483","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5
Abstract
Mother-to-infant transmission (MIT) is the leading cause of hepatitis B virus (HBV) infections globally. The aim of this international study was to assess the impediments to prevention of (MIT) of HBV.
METHODS
A cross-sectional survey was developed by the Federation of the International Societies for Pediatric Gastroenterology, Hepatology and Nutrition. (FISPGHAN) The survey was sent to HBV experts of the five member societies of FISPGHAN, and 63/91 countries/regions responded. Main outcome measures include percentage of countries having vaccine programs, timing of the first dose of HBV vaccine, availability of HBV vaccine for out-born neonates, payment of HBV vaccine and HBIG, screening HBV markers during pregnancy, and antivirals to highly infectious pregnant mothers.
RESULTS
Among the participating countries/regions, 11% did not implement infant HBV immunization programs. The first dose of vaccine was given >24 hours in 36% of the total countries and 100% of African countries. The recommended birth dose was unavailable for out-born neonates in 45% of the total countries, including 92% of African and 50% of Latin American countries/regions. During pregnancy, 44% countries do not screen maternal viral markers, and 46% do not provide third trimester antiviral therapy for highly viremic pregnant mothers.
CONCLUSIONS
Our study demonstrated multiple obstacles to achieving the goal of preventing MIT of HBV. Comprehensive public health programs to enhance vaccine coverage rate, supply HBV vaccine for out-born neonates, screening maternal HBV markers, treating highly viremic pregnant mothers are proposed to overcome these obstacles and achieve the goal of preventing MIT of HBV.